Title:
ALPHA-2-MACROGLOBULIN THERAPIES AND DRUG SCREENING METHODS FOR ALZHEIMER'S DISEASE
Document Type and Number:
WIPO Patent Application WO2000046246
Kind Code:
A8
Abstract:
The disclosed invention relates to the finding that the A2M-2 deletion mutation, which is a predisposing factor for Alzheimer's Disease, leads to the production of altered alpha 2M RNA transcripts and proteins. Based on this finding, the invention provides for new therapeutic agents for AD, including molecules having A beta and low density lipoprotein receptor-related protein (LRP) binding domains, peptides, nucleic acid molecules, antisense oligonucleotides, and viral vectors for gene therapy. In addition, the invention relates to pharmaceutical compositions containing these therapeutic agents, methods of using these therapeutic agents to combat Alzheimer's Disease, and methods of screening for therapeutic agents that can combat Alzheimer's Disease.
Inventors:
TANZI RUDOLPH E (US)
KOVACS DORA M (US)
SAUNDERS ALEISTER J (US)
KOVACS DORA M (US)
SAUNDERS ALEISTER J (US)
Application Number:
PCT/US2000/002412
Publication Date:
September 20, 2001
Filing Date:
February 02, 2000
Export Citation:
Assignee:
GEN HOSPITAL CORP (US)
TANZI RUDOLPH E (US)
KOVACS DORA M (US)
SAUNDERS ALEISTER J (US)
TANZI RUDOLPH E (US)
KOVACS DORA M (US)
SAUNDERS ALEISTER J (US)
International Classes:
C12N15/09; A61K31/7088; A61K35/76; A61K38/00; A61K45/00; A61K48/00; A61P25/28; C07K14/47; C07K14/81; C07K19/00; C12N7/00; C12N15/12; C12P19/34; C12Q1/02; C12Q1/68; C12Q1/6883; G01N27/447; G01N33/15; G01N33/50; G01N33/53; G01N33/68; C12R1/91; (IPC1-7): C07K14/47; A61K38/17; A61K48/00; A61P25/28; C12N15/11; C12N15/12; C12N15/86; C12Q1/68; G01N33/53
Download PDF:
Previous Patent: HUMAN ANTIBIOTIC PROTEINS
Next Patent: METHODS OF USE FOR DNA MOLECULES ENCODING M68, A TNF RECEPTOR-RELATED PROTEIN
Next Patent: METHODS OF USE FOR DNA MOLECULES ENCODING M68, A TNF RECEPTOR-RELATED PROTEIN